Zusammenfassung
Biologika und insbesondere therapeutische monoklonale Antikörper haben in den letzten Jahren einen regelrechten Siegeszug in der Therapie von entzündlichen und malignen Erkrankungen angetreten. Sie ermöglichen eine zielgerichtete Blockade von Zytokinen, Rezeptoren und anderen Moleküle. Die folgende Übersichtsarbeit skizziert die immunologischen Grundlagen, den gegenwärtigen Entwicklungsstand sowie zukünftige Entwicklungen dieser Therapeutika.
Abstract
Biologics and especially therapeutic monoclonal antibodies have an ever increasing impact in the therapy of inflammatory and malignant diseases. They allow a selective blockade of cytokines, receptors and other molecules. This review summarizes the immunological background, the current state and future trends in the development of these therapeutic agents.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Aggarwal S (2009) What’s fueling the biotech engine – 2008. Nat Biotechnol 27(11):987–993
Glaeske G, Schicktanz C (2010) BARMER GEK Arzneimittel-Report 2010, vol. Band 2. Asgard-Verlag, St. Augustin
Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495–497
Reichert JM (2008) Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 9(6):423–430
Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10(5):301–316
Williams-Skipp C, Raman T, Valuck RJ et al (2009) Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model. Arthritis Rheum 60(2):408–418
Bluml S, Binder NB, Niederreiter B et al (2010) Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum 62(6):1608–1619
Isaacs JD (2010) The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol 10(8):605–611
Suntharalingam G, Perry MR, Ward S et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018–1028
Strangfeld A, Hierse F, Kekow J et al (2009) Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68(12):1856–1862
Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10(5):345–352
Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69(12):4941–4944
Schellekens H, Moors E (2010) Clinical comparability and European biosimilar regulations. Nat Biotechnol 28(1):28–31
Sack U, Emmrich F (2008) Monoclonal antibodies. Principles, generation, application, and side effects. Internist (Berl) 49(8):919–928
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Frey, O., Kamradt, T. Biologika. Ophthalmologe 108, 7–12 (2011). https://doi.org/10.1007/s00347-010-2255-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00347-010-2255-z